Daxotel
Generic Name
Docetaxel
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| daxotel 20 mg injection | ৳ 3,500.00 | N/A |
| daxotel 80 mg injection | ৳ 10,000.00 | N/A |
Description
Overview of the medicine
Docetaxel (marketed as Daxotel) is an anti-cancer chemotherapy drug used to treat various types of cancer, including breast, non-small cell lung, prostate, gastric, and head and neck cancer. It works by interfering with cell division.
Uses & Indications
Dosage
Adults
Highly variable; depends on cancer type, patient condition, and concomitant therapies. Typically 75-100 mg/m² IV infusion over 1 hour every 3 weeks.
Elderly
Dosage adjustment may be required in elderly patients, especially those with hepatic impairment or reduced performance status.
Renal_impairment
No specific dose adjustment for mild to moderate renal impairment; caution advised in severe impairment due to limited data.
How to Take
Administered as an intravenous infusion over 1 hour, typically every 3 weeks. Premedication with oral corticosteroids (e.g., dexamethasone) is usually required to reduce hypersensitivity reactions and fluid retention.
Mechanism of Action
Docetaxel promotes the assembly of microtubules from tubulin dimers and inhibits their depolymerization, leading to the stabilization of microtubules. This results in the inhibition of mitotic cell division and ultimately apoptosis in rapidly proliferating cancer cells.
Pharmacokinetics
Onset
Rapid distribution into tissues after intravenous infusion.
Excretion
Primarily excreted in feces (approximately 75%) as metabolites, with a small amount excreted in urine (approximately 6%).
Half life
Triphasic elimination with a terminal half-life of 4-18 hours.
Absorption
Administered intravenously, resulting in 100% bioavailability.
Metabolism
Extensively metabolized in the liver by the CYP3A4 isoenzyme system.
Side Effects
Contraindications
- •Severe hypersensitivity to docetaxel or polysorbate 80
- •Baseline neutrophil count <1500 cells/mm³
- •Severe hepatic impairment
Drug Interactions
Live vaccines
Avoid concurrent use due to docetaxel's immunosuppressive effects.
CYP3A4 inducers (e.g., carbamazepine, rifampicin, phenytoin)
May decrease docetaxel plasma concentrations, potentially reducing efficacy.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir)
May significantly increase docetaxel plasma concentrations, increasing toxicity.
Storage
Store unopened vials at 2°C to 25°C (36°F to 77°F). Protect from light. Do not refrigerate or freeze after dilution.
Overdose
No specific antidote. Management involves symptomatic and supportive care. Expected complications include bone marrow suppression, peripheral neurotoxicity, and mucositis.
Pregnancy & Lactation
Pregnancy Category D: Docetaxel can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during treatment and for 6 months after. Not recommended during breastfeeding due to potential harm to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years when stored unopened, as per manufacturer's label. Reconstituted or diluted solutions have shorter stability.
Availability
Hospitals, specialized cancer centers
Approval Status
Approved by major regulatory bodies globally
Patent Status
Generics available, initial patent expired
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
